Key facts
- Holmusk’s last known valuation is $134.8M (Jan 2023).
- It has raised $113.8M across 1 recorded rounds; the latest was Early Stage VC ($30.0M) in Sep 2023.
- Notable investors include Johnson & Johnson JJDC, Optum Ventures, OCTAVE Capital (Singapore), Capikris Foundation, Health Catalyst Capital Management — 14 tracked in total.
- Holmusk has filed 1 Form D with the SEC, most recently Oct 2023 ($30.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Holmusk
Funding rounds
1 roundsAbout Holmusk
Developer of a real-world evidence platform designed to advance behavioral health analytics and improve clinical understanding. The company's platform incorporates a longitudinal de-identified database and more than one million patients, combines natural language processing, predictive disease models, and analytics dashboards, enabling researchers, healthcare providers, and payers to derive evidence-based insights for treatment development, care delivery optimization, and regulatory decision-making.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2015
- Employees
- 101
- Website
- holmusk.com/
- Ownership
- Privately Held (backing)
Holmusk doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Holmusk shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Holmusk in its N-PORT filings yet. We sweep new filings monthly.